In contrast, the inhibition of Nrf2 by either Keap1 overexpression, Nrf2-small interfering RNA or by an Nrf2 depleting drug leads to anti-cancer drug susceptibility of these cells [115,116]. This evidence concerns the gene NFE2L2 and cancer.